JAK阻害薬とアダリムマブで治療された関節リウマチ患者の主要心血管イベントと静脈血栓のリスク: ナショナルコホート
Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222824
Real-world population study of patients with RA provides reassuring data regarding the risks of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) in patients initiating a JAKinib versus adalimumab, including patients at high risk of cardiovascular diseases.